Nkarta Inc

NKTXNASDAQ · USD
2.95USD0.00 (+2.44%)
719

Nkarta Inc (NKTX) Covered Calls

As of September 21, 2026, NKTX has 2 covered call opportunities in the coming three months. Return ranges from 75.3 to 77.1% until expiration. Annualized return ranges from 182.1 to 468.9%. The nearest expiration is November 20, 2026. Maximum potential profit is $222.

Read more

Running NKTX covered calls helps you generate consistent income from Nkarta Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Nkarta Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best NKTX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if NKTX stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling NKTX covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Nkarta Inc covered call is worth writing.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells.

The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Income-focused investors, long-term NKTX holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling NKTX covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Nkarta Inc covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile55.95% Neutral
  • Market cap (M$)211
  • 52 weeks high-20.70%
  • 52 weeks low73.53%
  • Analyst recommendationStrong Buy
    1.25
  • Target price$10.83
    267.12% above the current stock price
  • Dividend
  • Payout ratio
  • Earnings date2026-11-10
  • P/E
  • Future P/E
  • EPS (ttm)-1.58
  • EPS growth next 5 years1.82%

As of September 21, 2026

2026-11-20605.0073.610.100.55222.0077.08468.92-3.47+0.342,3850.45
2027-02-191515.0073.610.050.65217.0075.35182.13-1.74+0.356000.60

As of September 21, 2026

Sell covered calls with the data behind you

Find the best NKTX covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial